



PRESS RELEASE

Affymetrix and IPSOGEN Collaborate to Develop and Market In-Vitro Diagnostic Cancer Tests

MARSEILLE, France and SANTA CLARA, Calif., August 28, 2007 – Affymetrix Inc. (Nasdaq: AFFX) and IPSOGEN, a leading molecular diagnostic company based in France and Connecticut, today announced that they have signed a Powered by Affymetrix™ (PbA) agreement. With this agreement, IPSOGEN gains non-exclusive access to Affymetrix microarray technology to develop and market in-vitro diagnostic (IVD) tests, initially for breast cancer, on a worldwide basis.

The PbA agreement enables IPSOGEN to incorporate Affymetrix arrays into its diagnostic products. The resulting microarray-based tests will enable clinicians to provide more efficient and complete methods to diagnose, classify and manage patients suffering from cancer.

“This agreement with Affymetrix, the world leader in microarray-based technology, provides IPSOGEN with the most advanced platform meeting the highest industry standards to support our new generation of IVD-profiling diagnostic products,” said Vincent Fert, president and CEO of IPSOGEN. “IPSOGEN’s strong expertise in delivering high medical value IVD products in the field of blood cancers will be leveraged together with our new PbA capabilities to expedite the launch of a range of innovative and unique IVD tests for guiding breast cancer therapies.”

“The microarray-based tools and applications in the Powered by Affymetrix™ program continue to accelerate the discovery and development of oncology diagnostics products,” said Noel Doheny, senior vice president, Molecular Diagnostics at Affymetrix. “This is the era of personalized medicine and we are pleased that another innovator in the molecular diagnostic field like IPSOGEN has adopted our proven technology platform.”

The Affymetrix line of diagnostic products includes the GeneChip® System 3000Dx (GCS3000Dx), the first microarray instrumentation system for molecular diagnostic laboratories. The GCS3000Dx has been granted regulatory clearance by the U.S. Food and Drug Administration and is CE marked in the European Union for In Vitro Diagnostic use. Affymetrix and its Powered by Affymetrix™ partners are developing array-based tests for use with this system. The custom-designed technology is being used in many applications, including clinical diagnostics, forensics, animal, industrial and food testing.

About IPSOGEN

IPSOGEN is a molecular diagnostic company focused on the development and commercialization of innovative diagnostic products to guide treatment options in cancers. IPSOGEN has built a comprehensive portfolio of unique products in blood cancers available in more than 50 countries all over the world to leading institutions involved in cancer care. IPSOGEN products are registered as IVD in Europe.

Leveraging its expertise in blood cancers, IPSOGEN has developed, in partnership with leading cancer institutions, a pipeline of diagnostic products in breast cancer.

IPSOGEN is headquartered in Marseille, France, and has its U.S. offices in New Haven, Connecticut. For more information about IPSOGEN, please visit www.ipsogen.com.

About Affymetrix

Affymetrix GeneChip® microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more complete view of the genome. These products continue to accelerate genetic research and enable scientists to develop diagnostics and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases.

Today, Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies, as well as leading academic, government and not-for-profit research institutes. More than 1,600 systems have been shipped around the world and more than 9,500 peer-reviewed papers have been published using the technology.

Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Sacramento, Calif., and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit the company's website at www.affymetrix.com.

Forward-looking Statements

All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks and uncertainties associated with the agreement with IPSOGEN discussed in this press release; risks of the company's ability to achieve and sustain higher levels of revenue, higher gross margins and reduced operating expenses; uncertainties relating to technological approaches, manufacturing and product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties relating to sole-source suppliers; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix' Form 10-K for the year ended December 31, 2006, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

NOTE: Affymetrix, the Affymetrix logo and GeneChip® are registered trademarks owned or used by Affymetrix Inc. Ipsogen and the Ipsogen logo are registered trademarks owned by Ipsogen.



Media Contact:

Andrew Noble
Associate Director, Corporate Communications
408-731-5571

Contact:

Vincent Fert
President and CEO
+33(0) 4 91 29 30 90

Investor Contact:

Doug Farrell
Vice President, Investor Relations
408-731-5285